Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Clarithromycin

Research Leaders

15 sponsors active, led by National Buruli ulcer Control Programme, Ghana Health Service, Accra, Ghana

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 2/3 (1)

Trial Status

Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (1)

Showing 1 of 1 trials
NCT01659437Phase 2/3CompletedPrimary

WHO Drug Study for Buruli Ulcer - Comparison of SR8 and CR8

Showing all 1 trials

Research Network

Common Treatments

  • Clarithromycin1
  • Streptomycin1

Active Sponsors

  • National Buruli ulcer Control Programme, Ghana Health Service, Accra, Ghana1
  • Noguchi Memorial Institute of Medical Research, Accra, Ghana1
  • Institute of Tropical Medicine, Antwerp, Belgium1
  • Kumasi Center for Collaborative Research into Tropical Medicine, Kumasi, Ghana1
  • Plastic Surgery and Burns Centre, Korle-Bu Teaching Hospital, Accra, Ghana1

Top Investigators

Activity Timeline